Sauvie Inc.
Edit

Sauvie Inc.

http://www.sauvieinc.com/
Last activity: 10.03.2025
Probably Closed
Categories: BioTechBuildingBusinessCommerceDevelopmentLifeManagementMarketPlanningResearch
Sauvie Inc. is a mission-driven biopharmaceutical company focused on sustainably building a premier oncology company. The name Sauvie has been derived from a French sentence, "sauver une vie" which means "to save a life." Sauvie was formed to embody this meaning in what we do with a vision to save lives. Sauvie aims to harness its development and commercialization strengths to achieve its mission; develop and deliver highly innovative therapies that target proven disease pathways to get back life for patients suffering with cancer. Sauvie's priorities are: 1) Drive near term value by advancing the current pipeline 2) Enhance our pipeline via R&D and acquisitions 3) Build a sustainable business through partnerships Sauvie's differentiation is derived by the Management Team's approach and successes: 1) Development and commercial wins in both start-up and big pharma environments 2) Disciplined approach to high quality planning and execution 3) Global lens to bring critical therapies to market 4) Operating with the highest ethical standards 5) Seek revenue opportunities to sustainably grow the organization 6) Creating a diversified risk/multiple shots on net platform company
Followers
505
Website visits
1.8K /mo.
Mentions
4
Employees: 1-10
Founded date: 2022

Investors 1

DateNameWebsite
11.11.2023Robin Hood...robinhoodv...

Mentions in press and media 4

DateTitleDescription
10.03.2025Promising Advances in Cancer Treatment: A Look at Recent Developments in Glioblastoma and Prostate Cancer TherapiesIn the ever-evolving landscape of cancer treatment, two recent developments stand out: the collaboration between DBP International AB and Vivo Biopharma LLC on SI-053, and the SECuRE trial's promising results for 67Cu-SAR-bisPSMA. Both init...
10.03.2025DBP International AB and Vivo Biopharma LLC Extend Asset Purchase and Collaboration Agreements for SI-053DBP International AB and Vivo Biopharma LLC Extend Asset Purchase and Collaboration Agreements for SI-053 Mon, Mar 10, 2025 06:00 CET Report this content Double Bond Pharmaceutical International AB (publ) ("DBP") and Vivo Biopharm...
19.09.2023Supplement to Press Release: DBP International AB and Vivo Biopharma LLC Enter into Asset Purchase and Collaboration agreements to Develop and Commercialize a novel Glioblastoma TreatmentSupplement to Press Release: DBP International AB and Vivo Biopharma LLC Enter into Asset Purchase and Collaboration agreements to Develop and Commercialize a novel Glioblastoma Treatment Tue, Sep 19, 2023 22:23 CET Report this content The ...
17.09.2023DBP International AB and Vivo Biopharma LLC Enter into Asset Purchase and Collaboration agreements to Develop and Commercialize a novel Glioblastoma TreatmentDBP International AB and Vivo Biopharma LLC Enter into Asset Purchase and Collaboration agreements to Develop and Commercialize a novel Glioblastoma Treatment Sun, Sep 17, 2023 11:00 CET Report this content Double Bond Pharmaceutical Intern...

Reviews 0

Sign up to leave a review

Sign up Log In